MajesTEC-3 Trial

[Slide 1] MajesTEC-3: PFS by Number of Expandedᵃ HRCAs 0 HRCAs 1 HRCA ≥2 HRCAs Estimated Estimated Estimated 36-mo PFS rate 36-mo PFS rate 36-mo PFS rate 100 100 100 90.1% Tec-Dara, 0 HRCAs 82.0% 80 80 Tec-Dara, 80 76.4% 1 HRCA Tec-Dara, % surviving without progression >2 HRCAs 60 60 60 40 31.9% 40 40 30.7% DPd/DVd, 0 HRCAs DPd/DVd, 20 Tec-Dara, n=52 20 Tec-Dara, n=105 1 HRCA 20 Tec-Dara, n=64 13.7% DPd/DVd, n=55 DPd/DVd. n=111 DPd/DVd, n=69 DPd/DVd, HR, 0.12 (95% CI, 0.04-0.30) HR, 0.19 (95% CI, 0.11-0.32) HR, 0.16 (95% CI, 0.08-0.29) >2 HRCAs 0 0 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 Months Months Months No. at risk No. at risk No. at risk Tec-Dara 52 50 46 45 45 45 44 44 44 43 42 28 15 8 3 0 Tec-Dara 105 93 87 84 84 82 81 79 79 78 78 54 34 13 3 0 0 Tec-Dara 64 54 52 49 49 47 46 45 44 43 41 26 19 6 3 0 DPd/DVd 55 51 46 39 34 32 32 29 26 22 19 12 8 3 0 0 DPd/DVd 111 97 82 71 61 55 49 47 44 41 34 20 10 7 2 1 0 DPd/DVd 69 56 47 39 34 29 22 17 13 11 11 7 1 1 1 0 Tec-Dara consistently improved PFS vs DPd/DVd, including in patients with ultra high-risk RRMM PHRCA number is defined as the number of abnormalities present from the following: del(17p). t(4;14), t(14;16), amp(1q21). or gain(1q21). 11 Presented by R Banerjee at the 31st European Hematology Association (EHA) Annual Meeting: June 11-14, 2026; Stockholm, Sweden --- [Slide 2] MajesTEC-3: PFS by Functional High-Risk Statusᵃ Estimated 100 36-mo PFS rate 89.9% Tec-Dara, not FHR after 1 prior LOT % surviving without progression 80 77.3% Tec-Dara, FHR after 1 prior LOT 60 40 35.9% & DPd/DVd, not FHR Not FHR after 1 prior LOT: Tec-Dara, n=82; DPd/DVd, n=94 after 1 prior LOT 20 HR, 0.11 (95% CI, 0.05-0.23) 0% FHR after 1 prior LOT: Tec-Dara, n=26; DPd/DVd, n=20 DPd/DVd, FHR after 1 prior LOT HR, 0.22 (95% CI, 0.08-0.62) 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 Months No. at risk Tec-Dara, not FHR after 1PL 82 78 78 77 77 74 74 72 71 70 69 46 30 15 3 0 0 DPd/DVd, not FHR after 1PL 94 86 73 65 59 53 47 45 39 38 36 24 13 7 2 1 0 Tec-Dara, FHR after 1PL 26 20 18 18 18 17 17 17 17 16 16 8 6 2 1 0 0 DPd/DVd, FHR after 1 PL 20 16 14 12 12 11 10 9 8 5 4 1 0 0 0 0 0 Tec-Dara substantially prolonged PFS vs DPd/DVd in patients with FHR MM, surpassing inferior outcomes historically seen with traditional therapies¹ 1PL, 1 prior LOT; MM, multiple myeloma. *Functional high-risk status defined as patients with 1 prior LOT and progressive disease within 18 months of ASCT or start of initial therapy. 1. Banerjee R, et al. Frontiers Oncol. 2023;13:1240966. 13 Presented by R Banerjee at the 31st European Hematology Association (EHA) Annual Meeting: June 11-14, 2026; Stockholm, Sweden --- [Slide 3] MajesTEC-3: PFS By Risk Status (ITT) Tec-Dara DPd/DVd Events Median Events Median n/N n/N HR (95% CI) PFS (mo) PFS (mo) Functional high risk 5/26 NE 14/20 23.2 0.22 (0.08-0.62) Non-functional high risk 8/82 NE 57/94 20.8 0.11 (0.05-0.23) Prespecified std. risk 15/126 NE 84/145 24.7 0.16 (0.09-0.27) Prespecified high risk 20/104 NE 78/104 14.4 0.15 (0.09-0.25) Expanded std. riskᵇ 5/52 NE 34/55 24.2 0.12 (0.04-0.30) Expanded high riskb 30/169 NE 122/180 15.8 0.18 (0.12-0.26) 1 HRCA 17/105 NE 69/111 17.9 0.19 (0.11-0.32) ≥2 HRCAs 13/64 NE 53/69 14.4 0.16 (0.08-0.29) 0.01 0.1 1 10 Tec-Dara better DPd/DVd better Tec-Dara consistently improved PFS vs DPd/DVd regardless of disease biology CI, confidence interval; HR hazard ratio; ITT, intent-to-treat; NE, not estimable; Std., standard Prespecified standard risk: none of del(17p), t(4;14), or t(14;16). Prespecified high risk: >1 of del(17p), t(4;14), or t(14;16). Expanded standard risk: none of del(17p), t(4;14), t(14;16), amp(1q21), or gain(1q21). Expanded high risk: >1 of del(17p), t(4;14), t(14;16), amp(1q21), or gain(1q21). 6 Presented by R Banerjee at the 31st European Hematology Association (EHA) Annual Meeting; June 11-14, 2026; Stockholm, Sweden --- [Slide 4] MajesTEC-3: PFS by Number of Expandedᵃ HRCAs 0 HRCAs 1 HRCA ≥2 HRCAs Estimated Estimated Estimated 36-mo PFS rate 36-mo PFS rate 36-mo PFS rate 100 100 100 90.1% Tec-Dara, 0 HRCAs 82.0% 80 80 Tec-Dara, 80 76.4% 1 HRCA Tec-Dara, % surviving without progression >2 HRCAs 60 60 60 40 31.9% 40 40 30.7% DPd/DVd, 0 HRCAs DPd/DVd, 20 Tec-Dara, n=52 20 Tec-Dara, n=105 1 HRCA 20 Tec-Dara, n=64 13.7% DPd/DVd, n=55 DPd/DVd. n=111 DPd/DVd, n=69 DPd/DVd, HR, 0.12 (95% CI, 0.04-0.30) HR, 0.19 (95% CI, 0.11-0.32) HR, 0.16 (95% CI, 0.08-0.29) >2 HRCAs 0 0 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 Months Months Months No. at risk No. at risk No. at risk Tec-Dara 52 50 46 45 45 45 44 44 44 43 42 28 15 8 3 0 Tec-Dara 105 93 87 84 84 82 81 79 79 78 78 54 34 13 3 0 0 Tec-Dara 64 54 52 49 49 47 46 45 44 43 41 26 19 6 3 0 DPd/DVd 55 51 46 39 34 32 32 29 26 22 19 12 8 3 0 0 DPd/DVd 111 97 82 71 61 55 49 47 44 41 34 20 10 7 2 1 0 DPd/DVd 69 56 47 39 34 29 22 17 13 11 11 7 1 1 1 0 Tec-Dara consistently improved PFS vs DPd/DVd, including in patients with ultra high-risk RRMM PHRCA number is defined as the number of abnormalities present from the following: del(17p). t(4;14), t(14;16), amp(1q21). or gain(1q21). 11 Presented by R Banerjee at the 31st European Hematology Association (EHA) Annual Meeting: June 11-14, 2026; Stockholm, Sweden --- [Slide 5] MajesTEC-3: PFS by Functional High-Risk Statusᵃ Estimated 100 36-mo PFS rate 89.9% Tec-Dara, not FHR after 1 prior LOT % surviving without progression 80 77.3% Tec-Dara, FHR after 1 prior LOT 60 40 35.9% & DPd/DVd, not FHR Not FHR after 1 prior LOT: Tec-Dara, n=82; DPd/DVd, n=94 after 1 prior LOT 20 HR, 0.11 (95% CI, 0.05-0.23) 0% FHR after 1 prior LOT: Tec-Dara, n=26; DPd/DVd, n=20 DPd/DVd, FHR after 1 prior LOT HR, 0.22 (95% CI, 0.08-0.62) 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 Months No. at risk Tec-Dara, not FHR after 1PL 82 78 78 77 77 74 74 72 71 70 69 46 30 15 3 0 0 DPd/DVd, not FHR after 1PL 94 86 73 65 59 53 47 45 39 38 36 24 13 7 2 1 0 Tec-Dara, FHR after 1PL 26 20 18 18 18 17 17 17 17 16 16 8 6 2 1 0 0 DPd/DVd, FHR after 1 PL 20 16 14 12 12 11 10 9 8 5 4 1 0 0 0 0 0 Tec-Dara substantially prolonged PFS vs DPd/DVd in patients with FHR MM, surpassing inferior outcomes historically seen with traditional therapies¹ 1PL, 1 prior LOT; MM, multiple myeloma. *Functional high-risk status defined as patients with 1 prior LOT and progressive disease within 18 months of ASCT or start of initial therapy. 1. Banerjee R, et al. Frontiers Oncol. 2023;13:1240966. 13 Presented by R Banerjee at the 31st European Hematology Association (EHA) Annual Meeting: June 11-14, 2026; Stockholm, Sweden --- [Slide 6] MajesTEC-3: PFS By Risk Status (ITT) Tec-Dara DPd/DVd Events Median Events Median n/N n/N HR (95% CI) PFS (mo) PFS (mo) Functional high risk 5/26 NE 14/20 23.2 0.22 (0.08-0.62) Non-functional high risk 8/82 NE 57/94 20.8 0.11 (0.05-0.23) Prespecified std. risk 15/126 NE 84/145 24.7 0.16 (0.09-0.27) Prespecified high risk 20/104 NE 78/104 14.4 0.15 (0.09-0.25) Expanded std. riskᵇ 5/52 NE 34/55 24.2 0.12 (0.04-0.30) Expanded high riskb 30/169 NE 122/180 15.8 0.18 (0.12-0.26) 1 HRCA 17/105 NE 69/111 17.9 0.19 (0.11-0.32) ≥2 HRCAs 13/64 NE 53/69 14.4 0.16 (0.08-0.29) 0.01 0.1 1 10 Tec-Dara better DPd/DVd better Tec-Dara consistently improved PFS vs DPd/DVd regardless of disease biology CI, confidence interval; HR hazard ratio; ITT, intent-to-treat; NE, not estimable; Std., standard Prespecified standard risk: none of del(17p), t(4;14), or t(14;16). Prespecified high risk: >1 of del(17p), t(4;14), or t(14;16). Expanded standard risk: none of del(17p), t(4;14), t(14;16), amp(1q21), or gain(1q21). Expanded high risk: >1 of del(17p), t(4;14), t(14;16), amp(1q21), or gain(1q21). 6 Presented by R Banerjee at the 31st European Hematology Association (EHA) Annual Meeting; June 11-14, 2026; Stockholm, Sweden

[Slide 1] Estimated 36-mo PFS rate 100 87.4% Tec-Dara, std. risk 80 77.7% % surviving without progression Tec-Dara, high risk 60 40 37.1% DPd/DVd, std. risk 20 11.5% DPd/DVd, high risk 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 Months

[Slide 1] MajesTEC-3: PFS By Risk Status (ITT) Tec-Dara DPd/DVd Events Median Events Median n/N PFS (mo) n/N HR (95% CI) PFS (mo) Functional high risk 5/26 NE 14/20 23.2 0.22 (0.08-0.62) Non-functional high risk 8/82 NE 57/94 20.8 0.11 (0.05-0.23) Prespecified std. risk 15/126 NE 84/145 24.7 0.16 (0.09-0.27) Prespecified high risk 20/104 NE 78/104 14.4 0.15 (0.09-0.25) Expanded std. riskᵇ 5/52 NE 34/55 24.2 0.12 (0.04-0.30) Expanded high riskᵇ 30/169 NE 122/180 15.8 0.18 (0.12-0.26) 1 HRCA 17/105 NE 69/111 17.9 0.19 (0.11-0.32) ≥2 HRCAs 13/64 NE 53/69 14.4 0.16 (0.08-0.29) 0.01 0.1 1 10 Tec-Dara better DPd/DVd better Tec-Dara consistently improved PFS vs DPd/DVd regardless of disease biology CI, confidence interval; HR hazard ratio; ITT. intent-to-treat; NE, not estimable; Std., standard "Prespecified standard risk: none of del(17p). 1(4;14), or 1(14;16). Prespecified high risk: >1 of del(17p). t(4;14). or t(14;16). Expanded standard risk: none of del(17p). t(4;14). t(14;16), amp(1q21). or gain(1q21). Expanded high risk: >1 of del(17p). t(4;14). t(14;16). amp(1q21). or gain(1q21). 6 Presented by R Banenee at the 31st European Hematology Association (EHA) Annual Meeting: June 11-14. 2026: Stockholm. Sweden --- [Slide 2] MajesTEC-3: PFS by Prespecifieda Cytogenetic Risk Estimated 100 36-mo PFS rate 87.4% Tec-Dara, std. risk % surviving without progression 80 Tec-Dara, high risk 77.7% 60 40 37.1% DPd/DVd, std. risk Std. risk: Tec-Dara, n=126; DPd/DVd, n=145 20 HR, 0.16 (95% CI, 0.09-0.27) High risk: Tec-Dara, n=104; DPd/DVd, n=104 11.5% DPd/DVd, high risk HR, 0.15 (95% CI, 0.09-0.25) 0 4 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 Months No. at risk Tec-Dara, std. risk 126 116 108 105 105 104 103 102 101 99 97 64 36 17 6 0 0 DPd/DVd, std. risk 145 131 115 99 87 82 78 73 69 62 53 34 20 10 2 1 0 Tec-Dara, high risk 104 89 86 82 82 79 77 75 74 73 71 47 31 10 3 0 0 DPd/DVd. high risk 104 85 71 61 53 45 35 30 24 20 18 10 2 2 1 0 0 Tec-Dara demonstrated superior PFS vs DPd/DVd regardless of cytogenetic risk and mirroring the overall study effect (HR 0.17)¹ "Prespecified standard risk: none of del(17p). t(4;14). or t(14;16). Prespecified high risk: 21 of del(17p). t(4;14). or t(14;16). 1. Costa LJ, et al. N Engl J Med. 2026,394(8):739-752. 7 Presented by R Banerjee at the 31st European Hematology Association (EHA) Annual Meeting: June 11-14, 2026; Stockholm, Sweden --- [Slide 3] MajesTEC-3: MRD-Negative ≥CR by Prespecified Cytogenetic Risk MRD-negative ≥CRᵃ (10⁻⁵) MRD-negative ≥CRᵃ (10⁻⁶) Tec-Dara 100 100 DPd/DVd 90 OR, 5.08 90 (95% CI, 2.90-8.88) OR, 12.83 OR, 8.29 80 80 (95% CI, 4.46-15.42) OR, 21.28 (95% CI, 5.77-28.53) (95% CI, 7.93-57.14) MRD-negative ≥CR rate, % 70 62.6 70 57.9 58.9 60 60 54.7 50 50 40 40 30 24.8 30 20 20 14.7 9.7 10 10 5.4 0 0 n=107 n=129 n=95 n=93 n=107 n=129 n=95 n=93 Prespecified std. riskb Prespecified high riskc Prespecified std. riskb Prespecified high riskc Tec-Dara substantially increased MRD-negative ≥CR rates, with an MRD-negative ≥CR (10⁻⁶) rate that was 10-fold that of DPd/DVd OR, odds ratio. "MRD-negative >CR refers to MRD negativity achieved within 3 months prior to achieving CR/sCR or at any time after CR/sCR and before progression or subsequent therapy. Assessed in the MRD NGS primary analysis set, defined as all randomized patients except those recruited in China (due to China instead utilizing NGF for MRD assessment). Prespecified standard risk: none of del(17p). 1(4;14), or 1(14;16). Prespecified high risk: 21 of del(17p), 1(4;14), or t(14;16). 8 Presented by R Banerjee at the 31st European Hematology Association (EHA) Annual Meeting: June 11-14, 2026; Stockholm, Sweden --- [Slide 4] MajesTEC-3: MRD-Negative ≥CR by Functional High-Risk Statusᵃ MRD-negative ≥CRb (10⁻⁵) MRD-negative ≥CRb (10⁻⁶) Tec-Dara DPd/DVd 100 100 90 OR, 4.47 90 OR, 5.95 80 (95% CI, 2.32-8.60) OR, 12.75 80 (95% CI, 2.98-11.88) (95% CI, 1.42-114.40) MRD-negative ≥CR rate, % 70 70 61.3 58.8 OR, NE 60 60 (95% CI, NE-NE) 50 42.9 50 38.1 40 40 30 26.1 30 19.3 20 20 10 5.6 10 0 0 0 n=80 n=88 n=21 n=18 n=80 n=88 n=21 n=18 Not FHR after 1 prior LOT FHR after 1 prior LOT Not FHR after 1 prior LOT FHR after 1 prior LOT Tec-Dara consistently increased MRD-negative >CR rates vs DPd/DVd at both 10⁻⁵ and the more stringent 10⁻⁶ threshold in patients with FHR MM Functional high-risk status defined as patients with 1 prior LOT and progressive disease within 18 months of ASCT or start of initial therapy. MRD-negative >CR refers to MRD negativity achieved within 3 months prior to achieving CR/sCR or at any time after CR/sCR and before progression or subsequent therapy. Assessed in the MRD NGS primary analysis set, defined as all randomized patients except those recruited in China (due to China instead utilizing NGF for MRD assessment). 14 Presented by R Banerjee at the 31st European Hematology Association (EHA) Annual Meeting: June 11-14, 2026; Stockholm, Sweden

[Slide 1] Teclistamab (RRMM): (Pts) With Relapsed Ratumumab and Rahul on Cytogenetic - Raphael Jin Lu," Banerjee, Charlotte 12 Niels WCJ Hamza Carson, " van de Hashmi, Agata Meletios . Donk? Caeiro, Weill Tyczynska, Roberto to Sun, Larry A 12 Dimopoulos, Alain 4: D Mina,' Kentos, Anderson 2 Markus Maria 19,20 Vania Hansson, Jr, Elena Victoria Hungria, Zamagni, a Mateos, Mark % na Anna Grey, Nizar Satosh K Surbhi Bahlis, Yoshihara, Charlotte Aurone # Kihyun Toftmann Perrot! Kim, Ajay Hansen, K Nooka, Institute, Consejo Fred Hulchinson Superior Emoy University Cancer de Conter, Adanta Vieyra, Sextle GA " USA Lijuan University Kang, of Hongmel Kristen Xu, Lantz, Ricardo " Anne Claudio Attar, Seifert, . Cerchione. Deborah * Salomon Briseno- Sidana, Manier Toomey, Paula * Jesis Rodriguez Paul Geerts, a Service Cirical Athers, SA, Medizinsche Cárdiba, Research d'Hematologie, School Argentina Kink of Center ACT for Hematologic Oncopole Certificate). Johnan Disease, Principal Toubute CBERONG Being France Ching Salamance Beigun Emay Washington, The Salamance Royal Spain Seate Ane Writing M de Cancer inestigición American Cance Haria University Christopher Medical " Chiu, Caigary Luciano Costa's Lina Otaro, . Case i I I / / 1 Göleborg Mediche Titala Cancer Scan Center Chirurgiche, Sweden Clinica Zeole Medicine The University The Athers, Nethertands, Bologra, Greece: to *2. *You Bologra, talk Car Bladipod styoge "Chica Kore, Neueger, Certano, The Natinomya, that Dresdien, Demany PRIN Copentages, Carata Terrary RCCS, Cancer Medicale, Center, New Spain True, * taly, NY, Badges law Center, Johnson Presented & Johnson, by TN R Ratan Banerjee "Johnson Lie, & France, PA "Cancer Dine Certer University Katara de CIMA, in Into at the 31st European Hematology Association (EHA) Annual Meeting: June No. 11-14, 2028; - Stockhaim, Sweden --- [Slide 2] Rahul Banerjee EHA2026 Congress eha

No OCR text captured for this slide.

No OCR text captured for this slide.